Treatment of Clinically Diagnosed Laryngopharyngeal Reflux Disease
- 15 November 2010
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 136 (11) , 1089-1092
Abstract
Objectives To determine the incidence of Helicobacter pylori (HP) stool antigen (HPSA) in patients with laryngopharyngeal reflux disease (LPRD), and to make a comparison of 2 treatment regimens that have been used based on the presence or absence of HPSA positivity in patients with LPRD. Design Randomized controlled study. Setting Suez Canal University Hospital, Ismalia, Egypt. Patients A total of 212 patients with symptoms of LPRD. Intervention Patients were evaluated by laryngoscopy, ambulatory pH monitoring for 24 hours, and HPSA testing. Esomeprazole magnesium as a monotherapy was evaluated vs triple therapy in patients with HP infection. Main Outcome Measures To determine the incidence of HPSA in patients with LPRD, and to make a comparison of 2 treatment regimens that have been used based on the presence or absence of HPSA positivity in patients with LPRD. Results Persistent dry cough and a feeling of a lump in the throat (globus sensation) were the most frequent symptoms of LPRD, while posterior laryngeal inflammation was the main laryngoscopic finding. Results from the HPSA test were positive in 57% of the studied group. Patients with negative HPSA were treated with esomeprazole as single modality with a reported improvement score of 96.6%. Patients with positive HPSA test results were divided into 2 groups: 1 received only esomeprazole, with reported improvement in 40%, whereas the second group was treated with esomeprazole, plus amoxicillin sodium and clarithromycin (triple therapy) and reported a 90% incidence of symptom improvement. Conclusion The incidence of HP infection in patients with LPRD in our study was 57%. Triple therapy showed a higher cure rate in patients with HPSA-positive test results.Keywords
This publication has 16 references indexed in Scilit:
- Laryngopharyngeal reflux: More questions than answersCleveland Clinic Journal of Medicine, 2010
- Helicobacter pylori: Molecular Genetics and Cellular Biology. Edited by Yoshio Yamaoka. Norfolk (United Kingdom): Caister Academic Press. $310.00. ix + 261 p.; ill.; index. ISBN: 978‐1‐904455‐31‐8. 2008.The Quarterly Review of Biology, 2010
- Management of laryngopharyngeal reflux with proton pump inhibitorsTherapeutics and Clinical Risk Management, 2008
- Helicobacter pylori Seropositivity Predicts Outcomes of Acid Suppression Therapy for Laryngopharyngeal Reflux SymptomsThe Laryngoscope, 2006
- Laryngopharyngeal reflux finding scores correlate with gastroesophageal reflux disease and Helicobacter pylori expressionActa Oto-Laryngologica, 2006
- The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) studyAlimentary Pharmacology & Therapeutics, 2003
- Diagnosis of Laryngopharyngeal Reflux Disease with Digital ImagingOtolaryngology–Head and Neck Surgery, 2003
- Detection of Helicobacter pylori in stool specimens by non-invasive antigen enzyme immunoassay in children: multicentre Italian studyBMJ, 2000
- Outcomes of Antireflux Therapy for the Treatment of Chronic LaryngitisAnnals of Otology, Rhinology & Laryngology, 1995
- Gastroesophageal reflux laryngitis resistant to omeprazole therapyJournal of Voice, 1995